Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: Findings from post hoc propensity-matched analysis of the AFFIRM trial

European Heart Journal

Volumn 34, Issue 20, 2013, Pages 1489-1497

  Gheorghiade, Mihai ^a   Fonarow, Gregg C ^b   Van Veldhuisen, Dirk J ^c   Cleland, John G F ^d   Butler, Javed ^e   Epstein, Andrew E ^f   Patel, Kanan ^g   Aban, Inmaculada B ^g   Aronow, Wilbert S ^h   Anker, Stefan D ⁱ   Ahmed, Ali ^g,j  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY OF HULL   (United Kingdom)

^e EMORY UNIVERSITY   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h NEW YORK MEDICAL COLLEGE   (United States)

ⁱ IRCCS SAN RAFFAELE PISANA   (Italy)

^j BIRMINGHAM VA MEDICAL CENTER   (United States)

more..

Author keywords

Atrial fibrillation; Digoxin; Hospitalization; Mortality; Propensity score

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; SOTALOL; VERAPAMIL;

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART RHYTHM; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PAROXYSMAL HEART ATRIUM FIBRILLATION; POST HOC ANALYSIS; PRIORITY JOURNAL; PROPENSITY SCORE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ATRIAL FIBRILLATION; DIGOXIN; HOSPITALIZATION; MORTALITY; PROPENSITY SCORE;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CAUSE OF DEATH; DIGOXIN; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PROPENSITY SCORE; TREATMENT OUTCOME;

EID: 84878285091     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht120     Document Type: Article

References (50)

1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995;155:469-473.
2. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH, European Heart Rhythm A, European Association for Cardio-Thoracic S. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31: 2369-2429.
3. The AFFIRM Investigators, Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-1833.
4. Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, Josephson RA, Kellen JC, Klein RC, Krahn AD, Mickel M, Mitchell LB, Nelson JD, Rosenberg Y, Schron E, Shemanski L, Waldo AL, Wyse DG, Investigators A. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004;109:1509-1513.
5. Whitbeck MG, Charnigo RJ, Khairy P, Ziada K, Bailey AL, Zegarra MM, Shah J, Morales G, Macaulay T, Sorrell VL, Campbell CL, Gurley J, Anaya P, Nasr H, Bai R, Di Biase L, Booth DC, Jondeau G, Natale A, Roy D, Smyth S, Moliterno DJ, Elayi CS. Increased mortality among patients taking digoxin analysis from the AFFIRM study. Eur Heart J. Advance Access published November 27, 2012, doi:10.1093/eurheartj/ehs348.
6. Hughes S. Increased Mortality with Digoxin in AF. 30 November 2012. Montreal: HeartWire. Medscape, LLC ('Medscape'). http://www.theheart.org/ article/ 1481335.do (15 December 2012)
7. Pittman G. Deaths More Common on Popular Heart Drug: Study. 28 November 2012. New York: Reuters Health. Available at: http://www.reuters.com/article/ 2012/11/ 28/us-deaths-more-idUSBRE8AR0KO20121128 (15 December 2012)
8. van Veldhuisen DJ, Van Gelder IC, Ahmed A, Gheorghiade M. Digoxin for patients with atrial fibrillation and heart failure: paradise lost or not? Eur Heart J. Advance Access published January 16, 2013, doi:10.1093/eurheartj/ ehs483.
9. Fisher LD, Lin DY. Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health 1999;20:145-157.
10. Rosenbaum PR, Rubin DB. The central role of propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
11. Rubin DB. Using propensity score to help design observational studies: Application to the tobacco litigation. Health Serv Outcomes Res Methodol 2001;2:169-188.
12. Ahmed A, Husain A, Love TE, Gambassi G, Dell'Italia LJ, Francis GS, Gheorghiade M, Allman RM, Meleth S, Bourge RC. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 2006;27:1431-1439.
13. Ahmed A, Rich MW, Love TE, Lloyd-Jones DM, Aban IB, Colucci WS, Adams KF, Gheorghiade M. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006;27: 178-186.
14. Heinze G, Juni P. An overview of the objectives of and the approaches to propensity score analyses. Eur Heart J 2011;32:1704-1708.
15. Austin PC. Primer on statistical interpretation or methods report card on propensity-score matching in the cardiology literature from 2004 to 2006: a systematic review. Circ Cardiovasc Qual Outcomes 2008;1:62-67.
16. The AFFIRM Investigators. Atrial fibrillation follow-up investigation of rhythm management - the AFFIRM study design. The Planning and Steering Committees of the AFFIRM study for the NHLBI AFFIRM investigators. Am J Cardiol 1997;79: 1198-1202.
17. The AFFIRM Investigators. Baseline characteristics of patients with atrial fibrillation: the AFFIRM Study. Am Heart J 2002;143:991-1001.
18. Luscher TF. In search of the right word: a statement of the HEART Group on scientific language. Eur Heart J 2013;34:7-9.
19. Olshansky B, Rosenfeld LE, Warner AL, Solomon AJ, O'Neill G, Sharma A, Platia E, Feld GK, Akiyama T, Brodsky MA, Greene HL, Investigators A. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 2004;43: 1201-1208.
20. Ahmed A, Fonarow GC, Zhang Y, Sanders PW, Allman RM, Arnett DK, Feller MA, Love TE, Aban IB, Levesque R, Ekundayo OJ, Dell'Italia LJ, Bakris GL, Rich MW. Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease. Am J Med 2012;125:399-410.
21. Patel K, Fonarow GC, Kitzman DW, Aban IB, Love TE, Allman RM, Gheorghiade M, Ahmed A. Angiotensin receptor blockers and outcomes in realworld older patients with heart failure and preserved ejection fraction: a propensity-matched inception cohort clinical effectiveness study. Eur J Heart Fail 2012;14:1179-1188.
22. Normand ST, Landrum MB, Guadagnoli E, Ayanian JZ, Ryan TJ, Cleary PD, McNeil BJ. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol 2001;54:387-398.
23. D'Agostino RB Jr. Propensity scores in cardiovascular research. Circulation 2007; 115:2340-2343.
24. Wahle C, Adamopoulos C, Ekundayo OJ, Mujib M, Aronow WS, Ahmed A. A propensity-matched study of outcomes of chronic heart failure (HF) in younger and older adults. Arch Gerontol Geriatr 2009;49:165-171.
25. Ahmed A, Rich MW, Zile M, Sanders PW, Patel K, Zhang Y, Aban IB, Love TE, Fonarow GC, Aronow WS, Allman RM. Renin-angiotensin inhibition in diastolic heart failure and chronic kidney disease. Am J Med 2013;126:150-161.
26. Ahmed A, Zannad F, Love TE, Tallaj J, Gheorghiade M, Ekundayo OJ, Pitt B. A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. Eur Heart J 2007;28:1334-1343.
27. Filippatos GS, Ahmed MI, Gladden JD, Mujib M, Aban IB, Love TE, Sanders PW, Pitt B, Anker SD, Ahmed A. Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data. Eur Heart J 2011;32:712-720.
28. Danaei G, Tavakkoli M, Hernan MA. Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol 2012;175:250-262.
29. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158:915-920.
30. Rosenbaum PR. Sensitivity to hidden bias. In: Rosenbaum PR ed., Observational Studies. New York: Springer-Verlag; 2002, p105-170.
31. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna W, Seward JB, Iwasaka T, Tsang TS. Incidence and mortality risk of congestive heart failure in atrial fibrillation patients: a community-based study over two decades. Eur Heart J 2006;27:936-941.
32. The Digitalis Investigation Group Investigators. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-533.
33. Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, Love TE, Aronow WS, Adams KF Jr., Gheorghiade M. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation 2006;114:397-403.
34. Ahmed MI, White M, Ekundayo OJ, Love TE, Aban I, Liu B, Aronow WS, Ahmed A. A history of atrial fibrillation and outcomes in chronic advanced systolic heart failure: a propensity-matched study. Eur Heart J 2009;30:2029-2037.
35. Tveit A, Flonaes B, Aaser E, Korneliussen K, Froland G, Gullestad L, Grundtvig M. No impact of atrial fibrillation on mortality risk in optimally treated heart failure patients. Clin Cardiol 2011;34:537-542.
36. Gheorghiade M, Hall VB, Jacobsen G, Alam M, Rosman H, Goldstein S. Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors. Circulation 1995;92:1801-1807.
37. van Veldhuisen DJ. Low-dose digoxin in patients with heart failure. Less toxic and at least as effective? J Am Coll Cardiol 2002;39:954-956.
38. van Veldhuisen DJ, Man in't Veld AJ, Dunselman PH, Lok DJ, Dohmen HJ, Poortermans JC, Withagen AJ, Pasteuning WH, Brouwer J, Lie KI. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). J Am Coll Cardiol 1993;22:1564-1573.
39. Ahmed A. Digoxin and reduction in mortality and hospitalization in geriatric heart failure: importance of low doses and low serum concentrations. J Gerontol A Biol Sci Med Sci 2007;62:323-329.
40. Ahmed A, Pitt B, Rahimtoola SH, Waagstein F, White M, Love TE, Braunwald E. Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. Int J Cardiol 2008;123: 138-146.
41. Ahmed A, Waagstein F, Pitt B, White M, Zannad F, Young JB, Rahimtoola SH. Effectiveness of digoxin in reducing one-year mortality in chronic heart failure in the Digitalis Investigation Group trial. Am J Cardiol 2009;103:82-87.
42. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289:871-878.
43. Schneider MP, Hua TA, Bohm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 2010;55:2299-2307.
44. Goette A, Staack T, Rocken C, Arndt M, Geller JC, Huth C, Ansorge S, Klein HU, Lendeckel U. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000;35:1669-1677.
45. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, Hillege HL, Bergsma-Kadijk JA, Cornel JH, Kamp O, Tukkie R, Bosker HA, Van Veldhuisen DJ, Van den Berg MP, Investigators RI. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010;362:1363-1373.
46. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS, Smith SC Jr, Priori SG, Estes NA III, Ezekowitz MD, Jackman WM, January CT, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Jacobs AK, Anderson JL, Albert N, Buller CE, Creager MA, Ettinger SM, Guyton RA, Hochman JS, Kushner FG, Ohman EM, Tarkington LG, Yancy CW, American College of Cardiology Foundation/American Heart Association Task F. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011;123:e269-e367.
47. Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 2003;42:1944-1951.
48. Cleland JG, Cullington D. Digoxin: quo vadis? Circ Heart Fail 2009;2:81-85.
49. Gheorghiade M, Patel K, Filippatos G, Anker SD, van Veldhuisen DJ, Cleland JG, Metra M, Aban IB, Greene SJ, Adams KF, McMurray JJ, Ahmed A. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail. Advance Access published Jan 25, 2013, doi:101093/eurjhf/hft010 2013.
50. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, Peto R. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 1999;150:341-353.